Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab. Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined. Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score. Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab / Damassi, A.; Cremante, M.; Signori, A.; Rebuzzi, S. E.; Malgeri, A.; Napoli, M. D.; Caffo, O.; Vignani, F.; Cavo, A.; Roviello, G.; Prati, V.; Tudini, M.; Atzori, F.; Messina, M.; Morelli, F.; Prati, G.; Nole, F.; Catalano, F.; Murianni, V.; Rescigno, P.; Banna, G. L.; Fornarini, G.; Buti, S.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 16:18-19(2024), pp. 1095-1103. [10.1080/1750743X.2024.2385881]
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
Caffo O.;
2024-01-01
Abstract
Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab. Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined. Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score. Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
IIMY_16_2385881.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
934.47 kB
Formato
Adobe PDF
|
934.47 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
